Researchers found that Lilly’s new drug, Jaypirca (pirtobrutinib), significantly reduces the risk of disease progression or death by 45% when used alongside a standard treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This finding comes from the BRUIN CLL-322 study, which is the first Phase 3 trial to show that adding pirtobrutinib to a venetoclax regimen is more effective than venetoclax alone. With nearly 640 participants, many of whom had previously been treated with other therapies, this study highlights a potential new approach for those struggling with these blood cancers.

For individuals looking to age well, this research is particularly relevant. CLL and SLL are types of blood cancer that can affect older adults, and effective treatment options can lead to improved outcomes and longer remissions. The study indicates that the combination treatment not only enhances effectiveness but also helps manage risks associated with the disease, potentially allowing patients to maintain a better quality of life during their treatment journey.

The evidence from the BRUIN CLL-322 study is promising but still in the early stages. While the results are encouraging, they are based on a randomized trial with a focus on progression-free survival (PFS) and other secondary endpoints. Overall survival data is still maturing, meaning it may take time to fully understand the long-term benefits and safety of this combination therapy. As Lilly prepares to submit these findings to regulatory authorities, it underscores the importance of ongoing research in improving treatment options for blood cancers.

Source: Lilly’s news release on Jaypirca